{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T21:19:35Z","timestamp":1782163175804,"version":"3.54.5"},"publisher-location":"New York, NY","reference-count":82,"publisher":"Springer US","isbn-type":[{"value":"9781071609033","type":"print"},{"value":"9781071609040","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-1-0716-0904-0_7","type":"book-chapter","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T13:03:37Z","timestamp":1595595817000},"page":"75-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recent Advances in DNA Repair Pathway and Its Application in Personalized Care of Metastatic Castration-Resistant Prostate Cancer (mCRPC)"],"prefix":"10.1007","author":[{"given":"Chenyang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanhua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,25]]},"reference":[{"issue":"6","key":"7_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"7_CR2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","volume":"5","author":"C Fitzmaurice","year":"2019","unstructured":"Fitzmaurice C, Abate D, Abbasi N et al (2019) Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 5(12):1749\u20131768","journal-title":"JAMA Oncol"},{"issue":"12","key":"7_CR3","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","volume":"4","author":"C Parker","year":"2018","unstructured":"Parker C, Lewington V, Shore N et al (2018) Targeted alpha therapy, an emerging class of cancer agents: a review. JAMA Oncol 4(12):1765\u20131772","journal-title":"JAMA Oncol"},{"key":"7_CR4","first-page":"i4405","volume":"355","author":"CR Ritch","year":"2016","unstructured":"Ritch CR, Cookson MS (2016) Advances in the management of castration resistant prostate cancer. BMJ (Clinical Research ed) 355:i4405","journal-title":"BMJ (Clinical Research ed)"},{"issue":"1","key":"7_CR5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","volume":"75","author":"P Nuhn","year":"2019","unstructured":"Nuhn P, De Bono JS, Fizazi K et al (2019) Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol 75(1):88\u201399","journal-title":"Eur Urol"},{"issue":"4","key":"7_CR6","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamaoncol.2017.3159","volume":"4","author":"N Almassi","year":"2018","unstructured":"Almassi N, Reichard C, Li J et al (2018) HSD3B1 and response to a nonsteroidal CYP17A1 inhibitor in castration-resistant prostate cancer. JAMA Oncol 4(4):554\u2013557","journal-title":"JAMA Oncol"},{"issue":"1","key":"7_CR7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2017.08.035","volume":"74","author":"K Miller","year":"2018","unstructured":"Miller K, Carles J, Gschwend JE et al (2018) The Phase 3 COU-AA-302 Study of abiraterone acetate plus prednisone in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: stratified analysis based on pain, prostate-specific antigen, and gleason score. Eur Urol 74(1):17\u201323","journal-title":"Eur Urol"},{"issue":"4","key":"7_CR8","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352\u2013360","journal-title":"N Engl J Med"},{"issue":"1","key":"7_CR9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.eururo.2017.09.038","volume":"74","author":"K Saito","year":"2018","unstructured":"Saito K, Fujii Y (2018) Antitumor activity and safety of enzalutamide after abiraterone acetate: seeking the optimal treatment sequence for castration-resistant prostate cancer patients. Eur Urol 74(1):46\u201347","journal-title":"Eur Urol"},{"issue":"14","key":"7_CR10","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJMc1810065","volume":"379","author":"MS Anker","year":"2018","unstructured":"Anker MS, Lehmann LH, Anker SD (2018) Enzalutamide in castration-resistant prostate cancer. N Engl J Med 379(14):1380","journal-title":"N Engl J Med"},{"issue":"28","key":"7_CR11","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1200\/JCO.2017.72.4138","volume":"35","author":"ES Antonarakis","year":"2017","unstructured":"Antonarakis ES, Tagawa ST, Galletti G et al (2017) Randomized, noncomparative, phase II trial of early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-na\u00efve, metastatic, castration-resistant prostate cancer. J Clin Oncol 35(28):3181\u20133188","journal-title":"J Clin Oncol"},{"issue":"12","key":"7_CR12","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41416-019-0611-6","volume":"121","author":"M Rouyer","year":"2019","unstructured":"Rouyer M, Oudard S, Joly F et al (2019) Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort. Br J Cancer 121(12):1001\u20131008","journal-title":"Br J Cancer"},{"issue":"8","key":"7_CR13","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdy232","volume":"29","author":"AR Hansen","year":"2018","unstructured":"Hansen AR, Massard C, Ott PA et al (2018) Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol 29(8):1807\u20131813","journal-title":"Ann Oncol"},{"issue":"4","key":"7_CR14","doi-asserted-by":"crossref","first-page":"djw261","DOI":"10.1093\/jnci\/djw261","volume":"109","author":"JL Gulley","year":"2017","unstructured":"Gulley JL, Madan RA, Pachynski R et al (2017) Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J Natl Cancer Inst 109(4):djw261","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"7_CR15","first-page":"597","volume":"55","author":"SH Lang","year":"2019","unstructured":"Lang SH, Swift SL, White H et al (2019) A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer. Int J Oncol 55(3):597\u2013616","journal-title":"Int J Oncol"},{"issue":"9","key":"7_CR16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","volume":"15","author":"A Ashworth","year":"2018","unstructured":"Ashworth A, Lord CJ (2018) Synthetic lethal therapies for cancer: what\u2019s next after PARP inhibitors? Nat Rev Clin Oncol 15(9):564\u2013576","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"7_CR17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"issue":"8","key":"7_CR18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","volume":"18","author":"HHY Chang","year":"2017","unstructured":"Chang HHY, Pannunzio NR, Adachi N et al (2017) Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol 18(8):495\u2013506","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"7_CR19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrg2380","volume":"9","author":"KW Caldecott","year":"2008","unstructured":"Caldecott KW (2008) Single-strand break repair and genetic disease. Nat Rev Genet 9(8):619\u2013631","journal-title":"Nat Rev Genet"},{"issue":"27","key":"7_CR20","doi-asserted-by":"crossref","first-page":"10502","DOI":"10.1074\/jbc.TM118.000371","volume":"293","author":"J Her","year":"2018","unstructured":"Her J, Bunting SF (2018) How cells ensure correct repair of DNA double-strand breaks. J Biol Chem 293(27):10502\u201310511","journal-title":"J Biol Chem"},{"issue":"4","key":"7_CR21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cell.2011.03.041","volume":"145","author":"K Schlacher","year":"2011","unstructured":"Schlacher K, Christ N, Siaud N et al (2011) Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 145(4):529\u2013542","journal-title":"Cell"},{"issue":"10","key":"7_CR22","doi-asserted-by":"crossref","first-page":"a012732","DOI":"10.1101\/cshperspect.a012732","volume":"5","author":"C Clauson","year":"2013","unstructured":"Clauson C, Sch\u00e4rer OD, Niedernhofer L (2013) Advances in understanding the complex mechanisms of DNA interstrand cross-link repair. Cold Spring Harb Perspect Biol 5(10):a012732","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"7676","key":"7_CR23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature24060","volume":"550","author":"W Zhao","year":"2017","unstructured":"Zhao W, Steinfeld JB, Liang F et al (2017) BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. Nature 550(7676):360\u2013365","journal-title":"Nature"},{"issue":"44","key":"7_CR24","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","volume":"105","author":"S Rottenberg","year":"2008","unstructured":"Rottenberg S, Jaspers JE, Kersbergen A et al (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 105(44):17079\u201317084","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"7_CR25","first-page":"4842","volume":"61","author":"ME Moynahan","year":"2001","unstructured":"Moynahan ME, Cui TY, Jasin M (2001) Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 61(12):4842\u20134850","journal-title":"Cancer Res"},{"key":"7_CR26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2210-11-7","volume":"11","author":"E Alli","year":"2011","unstructured":"Alli E, Sharma VB, Hartman AR et al (2011) Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol 11:7","journal-title":"BMC Pharmacol"},{"issue":"7316","key":"7_CR27","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nature09399","volume":"467","author":"RB Jensen","year":"2010","unstructured":"Jensen RB, Carreira A, Kowalczykowski SC (2010) Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 467(7316):678\u2013683","journal-title":"Nature"},{"issue":"7","key":"7_CR28","doi-asserted-by":"crossref","first-page":"djw302","DOI":"10.1093\/jnci\/djw302","volume":"109","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Mcguffog L, Barrowdale D et al (2017) Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 109(7):djw302","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"7_CR29","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117\u20131130","journal-title":"Am J Hum Genet"},{"issue":"11","key":"7_CR30","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812\u2013822","journal-title":"J Natl Cancer Inst"},{"issue":"7418","key":"7_CR31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61\u201370","journal-title":"Nature"},{"issue":"4","key":"7_CR32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/jclinpath-2019-206276","volume":"73","author":"LA Teixeira","year":"2020","unstructured":"Teixeira LA, Candido Dos Reis FJ (2020) Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review. J Clin Pathol 73(4):191\u2013196","journal-title":"J Clin Pathol"},{"issue":"5","key":"7_CR33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ccr.2013.03.025","volume":"23","author":"M Li","year":"2013","unstructured":"Li M, Yu X (2013) Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. Cancer Cell 23(5):693\u2013704","journal-title":"Cancer Cell"},{"issue":"1","key":"7_CR34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/ncb3445","volume":"19","author":"AH Rezaeian","year":"2017","unstructured":"Rezaeian AH, Li CF, Wu CY et al (2017) A hypoxia-responsive TRAF6-ATM-H2AX signalling axis promotes HIF1\u03b1 activation, tumorigenesis and\u00a0metastasis. Nat Cell Biol 19(1):38\u201351","journal-title":"Nat Cell Biol"},{"issue":"4","key":"7_CR35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/PAI.0000000000000786","volume":"28","author":"RM Miller","year":"2020","unstructured":"Miller RM, Nworu C, Mckee L et al (2020) Development of an immunohistochemical assay to detect the ataxia-telangiectasia mutated (ATM) protein in gastric carcinoma. Appl Immunohistochem Mol Morphol 28(4):303\u2013310","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"7","key":"7_CR36","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41416-019-0565-8","volume":"121","author":"NR Jette","year":"2019","unstructured":"Jette NR, Radhamani S, Arthur G et al (2019) Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated\/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells. Br J Cancer 121(7):600\u2013610","journal-title":"Br J Cancer"},{"issue":"22","key":"7_CR37","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","volume":"61","author":"KM Foote","year":"2018","unstructured":"Foote KM, Nissink JWM, Mcguire T et al (2018) Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) Kinase with application as an anticancer agent. J Med Chem 61(22):9889\u20139907","journal-title":"J Med Chem"},{"key":"7_CR38","doi-asserted-by":"crossref","first-page":"107450","DOI":"10.1016\/j.pharmthera.2019.107450","volume":"207","author":"A Bradbury","year":"2019","unstructured":"Bradbury A, Hall S, Curtin N et al (2019) Targeting ATR as cancer therapy: a new era for synthetic lethality and synergistic combinations? Pharmacol Ther 207:107450","journal-title":"Pharmacol Ther"},{"issue":"5","key":"7_CR39","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF et al (2016) Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 375(5):443\u2013453","journal-title":"N Engl J Med"},{"issue":"3","key":"7_CR40","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","volume":"66","author":"EK Bancroft","year":"2014","unstructured":"Bancroft EK, Page EC, Castro E et al (2014) Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol 66(3):489\u2013499","journal-title":"Eur Urol"},{"issue":"14","key":"7_CR41","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","volume":"31","author":"E Castro","year":"2013","unstructured":"Castro E, Goh C, Olmos D et al (2013) Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 31(14):1748\u20131757","journal-title":"J Clin Oncol"},{"issue":"5","key":"7_CR42","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","volume":"71","author":"R Na","year":"2017","unstructured":"Na R, Zheng SL, Han M et al (2017) Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol 71(5):740\u2013747","journal-title":"Eur Urol"},{"issue":"6","key":"7_CR43","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","volume":"37","author":"E Castro","year":"2019","unstructured":"Castro E, Romero-Laorden N, Del Pozo A et al (2019) PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol 37(6):490\u2013503","journal-title":"J Clin Oncol"},{"issue":"5","key":"7_CR44","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","volume":"75","author":"H Carter","year":"2019","unstructured":"Carter H, Helfand B, Mamawala M et al (2019) Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer. Eur Urol 75(5):743\u2013749","journal-title":"Eur Urol"},{"issue":"5","key":"7_CR45","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161(5):1215\u20131228","journal-title":"Cell"},{"key":"7_CR46","first-page":"10","volume":"2017","author":"W Abida","year":"2017","unstructured":"Abida W, Armenia J, Gopalan A et al (2017) Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol 2017:10","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"7_CR47","doi-asserted-by":"crossref","first-page":"e010332","DOI":"10.1136\/bmjopen-2015-010332","volume":"6","author":"SN Hart","year":"2016","unstructured":"Hart SN, Ellingson MS, Schahl K et al (2016) Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open 6(4):e010332","journal-title":"BMJ Open"},{"issue":"5","key":"7_CR48","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2012.08.053","volume":"63","author":"H Beltran","year":"2013","unstructured":"Beltran H, Yelensky R, Frampton GM et al (2013) Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 63(5):920\u2013926","journal-title":"Eur Urol"},{"issue":"7406","key":"7_CR49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso CS, Wu YM, Robinson DR et al (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487(7406):239\u2013243","journal-title":"Nature"},{"issue":"6","key":"7_CR50","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.molcel.2015.06.006","volume":"58","author":"K Wl","year":"2015","unstructured":"Wl K (2015) PARPs and ADP-ribosylation: 50 years \u2026 and counting. Mol Cell 58(6):902\u2013910","journal-title":"Mol Cell"},{"issue":"19","key":"7_CR51","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1093\/nar\/gkg761","volume":"31","author":"SF El-Khamisy","year":"2003","unstructured":"El-Khamisy SF, Masutani M, Suzuki H et al (2003) A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res 31(19):5526\u20135533","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"7_CR52","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1101\/gad.183509.111","volume":"26","author":"X Luo","year":"2012","unstructured":"Luo X, Kraus WL (2012) On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 26(5):417\u2013432","journal-title":"Genes Dev"},{"issue":"5","key":"7_CR53","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1073\/pnas.0904783107","volume":"107","author":"DC Hegan","year":"2010","unstructured":"Hegan DC, Lu Y, Stachelek GC et al (2010) Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci U S A 107(5):2201\u20132206","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"7_CR54","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1541-7786.MCR-13-0672","volume":"12","author":"MJ Schiewer","year":"2014","unstructured":"Schiewer MJ, Knudsen KE (2014) Transcriptional roles of PARP1 in cancer. Mol Cancer Res 12(8):1069\u20131080","journal-title":"Mol Cancer Res"},{"key":"7_CR55","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.sbi.2018.11.002","volume":"53","author":"MF Langelier","year":"2018","unstructured":"Langelier MF, Eisemann T, Riccio AA et al (2018) PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification. Curr Opin Struct Biol 53:187\u2013198","journal-title":"Curr Opin Struct Biol"},{"issue":"5","key":"7_CR56","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/annonc\/mdw048","volume":"27","author":"T Helleday","year":"2016","unstructured":"Helleday T (2016) PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations. Ann Oncol 27(5):755\u2013757","journal-title":"Ann Oncol"},{"issue":"3","key":"7_CR57","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Ronnie S-F, Schmutzler Rita K et al (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol 33(3):244\u2013250","journal-title":"J Clin Oncol"},{"issue":"18","key":"7_CR58","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S et al (2015) DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373(18):1697\u20131708","journal-title":"N Engl J Med"},{"issue":"1","key":"7_CR59","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","volume":"21","author":"J Mateo","year":"2019","unstructured":"Mateo J, Porta N, Bianchini D et al (2019) Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 21(1):162\u2013174","journal-title":"Lancet Oncol"},{"issue":"1","key":"7_CR60","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","volume":"20","author":"CJ Lafargue","year":"2019","unstructured":"Lafargue CJ, Molin GZD, Sood AK et al (2019) Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 20(1):e15\u2013e28","journal-title":"Lancet Oncol"},{"issue":"7","key":"7_CR61","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","volume":"19","author":"N Clarke","year":"2018","unstructured":"Clarke N, Wiechno P, Alekseev B et al (2018) Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 19(7):975\u2013986","journal-title":"Lancet Oncol"},{"issue":"21","key":"7_CR62","doi-asserted-by":"crossref","first-page":"e103479","DOI":"10.15252\/embj.2019103479","volume":"38","author":"B Heyman","year":"2019","unstructured":"Heyman B, Jamieson C (2019) To PARP or not to PARP?-Toward sensitizing acute myeloid leukemia stem cells to immunotherapy. EMBO J 38(21):e103479","journal-title":"EMBO J"},{"issue":"12","key":"7_CR63","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.3390\/ijms19123793","volume":"19","author":"M C\u00e9saire","year":"2018","unstructured":"C\u00e9saire M, Thariat J, Cand\u00e9ias SM et al (2018) Combining PARP inhibition, radiation, and immunotherapy: a possible strategy to improve the treatment of cancer? Int J Mol Sci 19(12):3793","journal-title":"Int J Mol Sci"},{"issue":"7_suppl","key":"7_CR64","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.2019.37.7_suppl.145","volume":"37","author":"Y Evan","year":"2019","unstructured":"Evan Y, Yu MC, Margitta R et al (2019) Keynote-365 cohort a: pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol 37(7_suppl):145","journal-title":"J Clin Oncol"},{"issue":"1","key":"7_CR65","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","volume":"6","author":"F Karzai","year":"2018","unstructured":"Karzai F, Vanderweele D, Madan RA et al (2018) Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer 6(1):141","journal-title":"J Immunother Cancer"},{"issue":"7","key":"7_CR66","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/14656566.2018.1464557","volume":"19","author":"I Sabatucci","year":"2018","unstructured":"Sabatucci I, Maltese G, Lepori S et al (2018) Rucaparib: a new treatment option for ovarian cancer. Expert Opin Pharmacother 19(7):765\u2013771","journal-title":"Expert Opin Pharmacother"},{"issue":"15_suppl","key":"7_CR67","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1200\/JCO.2019.37.15_suppl.5031","volume":"37","author":"W Abida","year":"2019","unstructured":"Abida W, Bryce AH, Vogelzang NJ et al (2019) Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2. J Clin Oncol 37(15_suppl):5031","journal-title":"J Clin Oncol"},{"issue":"17","key":"7_CR68","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-18-0042","volume":"24","author":"G Ison","year":"2018","unstructured":"Ison G, Howie LJ, Amiri-Kordestani L et al (2018) FDA Approval summary: niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy. Clin Cancer Res 24(17):4066\u20134071","journal-title":"Clin Cancer Res"},{"issue":"9","key":"7_CR69","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","volume":"14","author":"SK Sandhu","year":"2013","unstructured":"Sandhu SK, Schelman WR, Wilding G et al (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14(9):882\u2013892","journal-title":"Lancet Oncol"},{"issue":"7_suppl","key":"7_CR70","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.2019.37.7_suppl.202","volume":"37","author":"MR Smith","year":"2019","unstructured":"Smith MR, Kaur SS, Kevin KW et al (2019) Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): preliminary results of GALAHAD. J Clin Oncol 37(7_suppl):202","journal-title":"J Clin Oncol"},{"issue":"1","key":"7_CR71","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10637-019-00867-4","volume":"38","author":"S Boussios","year":"2020","unstructured":"Boussios S, Karihtala P, Moschetta M et al (2020) Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest New Drugs 38(1):181\u2013193","journal-title":"Invest New Drugs"},{"key":"7_CR72","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ebiom.2018.12.060","volume":"40","author":"R Tuli","year":"2019","unstructured":"Tuli R, Shiao SL, Nissen N et al (2019) A phase 1 study of veliparib, a PARP-1\/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine 40:375\u2013381","journal-title":"EBioMedicine"},{"issue":"3","key":"7_CR73","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.18.00264","volume":"37","author":"TK Owonikoko","year":"2019","unstructured":"Owonikoko TK, Dahlberg SE, Sica GL et al (2019) Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol 37(3):222\u2013229","journal-title":"J Clin Oncol"},{"issue":"4","key":"7_CR74","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl S, O\u2019shaughnessy J, Untch M et al (2018) Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 19(4):497\u2013509","journal-title":"Lancet Oncol"},{"issue":"5_suppl","key":"7_CR75","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1200\/jco.2012.30.5_suppl.224","volume":"30","author":"M Hussain","year":"2012","unstructured":"Hussain M, Anthony CM, Slovin Susan F et al (2012) Pilot study of veliparib (ABT-888) with temozolomide (TMZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 30(5_suppl):224\u2013224","journal-title":"J Clin Oncol"},{"issue":"7_suppl","key":"7_CR76","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1200\/jco.2015.33.7_suppl.170","volume":"33","author":"S Pahuja","year":"2015","unstructured":"Pahuja S, Joseph AL, Prakash BC et al (2015) Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 33(7_suppl):170","journal-title":"J Clin Oncol"},{"issue":"10","key":"7_CR77","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1200\/JCO.2017.75.7310","volume":"36","author":"M Hussain","year":"2018","unstructured":"Hussain M, Daignault-Newton S, Twardowski PW et al (2018) Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012. J Clin Oncol 36(10):991\u2013999","journal-title":"J Clin Oncol"},{"issue":"21","key":"7_CR78","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB et al (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72(21):5588\u20135599","journal-title":"Cancer Res"},{"issue":"18","key":"7_CR79","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s40265-018-1026-z","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy SM (2018) Talazoparib: first global approval. Drugs 78(18):1939\u20131946","journal-title":"Drugs"},{"issue":"7_suppl","key":"7_CR80","doi-asserted-by":"crossref","first-page":"TPS342","DOI":"10.1200\/JCO.2019.37.7_suppl.TPS342","volume":"37","author":"JS De Bono","year":"2019","unstructured":"De Bono JS, Higano Celestia S, Fred S et al (2019) TALAPRO-1: an open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair (DDR) defects and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on greater than or equal to one novel hormonal therapy (NHT). J Clin Oncol 37(7_suppl):TPS342\u2013TPS342","journal-title":"J Clin Oncol"},{"issue":"9","key":"7_CR81","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","volume":"20","author":"M Friedlander","year":"2019","unstructured":"Friedlander M, Meniawy T, Markman B et al (2019) Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial. Lancet Oncol 20(9):1306\u20131315","journal-title":"Lancet Oncol"},{"issue":"2","key":"7_CR82","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.canlet.2013.10.034","volume":"343","author":"LA Mcpherson","year":"2014","unstructured":"Mcpherson LA, Shen Y, Ford JM (2014) Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells. Cancer Lett 343(2):217\u2013223","journal-title":"Cancer Lett"}],"container-title":["Methods in Molecular Biology","Precision Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-0904-0_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T13:38:48Z","timestamp":1595597928000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-0716-0904-0_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9781071609033","9781071609040"],"references-count":82,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-0904-0_7","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"25 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}